InflaRx's GOHIBIC Tapped for BARDA ARDS Trial
Ticker: IFRX · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1708688
Sentiment: bullish
Topics: clinical-trial, government-funding, ARDS, drug-development
Related Tickers: IFRX
TL;DR
InflaRx's GOHIBIC is in the first BARDA-backed ARDS trial, big news for the company.
AI Summary
On June 24, 2024, InflaRx N.V. announced that its GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA) for the first BARDA-sponsored clinical trial evaluating host-directed therapeutics for Acute Respiratory Distress Syndrome (ARDS). GOHIBIC is an anti-C5a monoclonal antibody previously authorized under FDA Emergency Use Authorization for COVID-19 treatment.
Why It Matters
This BARDA selection signifies significant government interest and potential funding for GOHIBIC's development beyond COVID-19, potentially opening a new therapeutic avenue for ARDS.
Risk Assessment
Risk Level: medium — While BARDA selection is positive, the trial is in its early stages, and regulatory approval for ARDS is not guaranteed.
Key Players & Entities
- InflaRx N.V. (company) — Registrant and developer of GOHIBIC
- GOHIBIC (vilobelimab) (drug) — Investigational therapeutic for ARDS and COVID-19
- Biomedical Advanced Research and Development Authority (BARDA) (company) — Sponsoring the new clinical trial
- Acute Respiratory Distress Syndrome (ARDS) (medical_condition) — The condition being studied in the new trial
- FDA (company) — Granted Emergency Use Authorization for GOHIBIC
- June 24, 2024 (date) — Date of the press release and filing
FAQ
What is the specific role of GOHIBIC (vilobelimab) in the new BARDA-sponsored trial for ARDS?
GOHIBIC (vilobelimab) is being evaluated as a novel host-directed therapeutic for Acute Respiratory Distress Syndrome (ARDS) in the first BARDA-sponsored clinical trial.
What is BARDA's significance in this announcement?
BARDA's selection of GOHIBIC for this trial indicates a significant endorsement and potential for government support in the development of the drug for ARDS.
What prior authorization does GOHIBIC have from the FDA?
GOHIBIC has previously been authorized under FDA Emergency Use Authorization (EUA) for the treatment of COVID-19.
What is the primary focus of the new clinical trial announced on June 24, 2024?
The primary focus is to evaluate novel host-directed therapeutics, specifically GOHIBIC, for Acute Respiratory Distress Syndrome (ARDS).
What type of drug is GOHIBIC (vilobelimab)?
GOHIBIC (vilobelimab) is an anti-C5a monoclonal antibody.
Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-06-24 16:16:48
Filing Documents
- ny20030768x2_6k.htm (6-K) — 9KB
- ny20030768x2_ex99-1.htm (EX-99.1) — 25KB
- logo_inflarx.jpg (GRAPHIC) — 14KB
- 0001140361-24-031097.txt ( ) — 55KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: June 24, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer